ProlacSan probiotic lozenges and gels contain L. plantarum and L. brevis strains with proven in vitro antimicrobial activity against P. gingivalis. In our study we aim to investigate proposed benefit of ProlacSan as adjunct to conventional initial periodontal treatment in a group (n = 40) of Grade III and IV periodontitis patients. Patients will be randomized in two groups receiving either probiotic (n = 20) or placebo (n = 20) after completion of nonsurgical treatment within 7 days. Before treatment and after three months, standard periodontal parameters will be measured by masked examiner and plaque samples harvested for cultivation of 9 most relevant periodontal pathogens. One lozenge per day of probiotic/placebo will be used during 3 months healing period. Primary outcome measures will be the number of persisting sites per patient that need additional surgical treatment defined as sites with probing depth \> 4 mm and bleeding on probing.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Enrollment
40
Probiotic strains
Similar to ProlacSan lozenges in taste in colour
University Dental Clinic
Ljubljana, Slovenia
Residual diseased site number
No of sites with probing pocket depth (PPD) \> 4 mm and bleeding on probing after treatment
Time frame: 3 months
Gingival bleeding index
Percentage od bleeding sites after gentle probing of gingival sulcus
Time frame: 3 months
Probing pocket depth reduction
Change in probing pocket depth
Time frame: 3 months
Recession
Change of the position of the gingival margin
Time frame: 3 months
Bleeding on probing
Bleeding after measurement of pocket depth
Time frame: 3 months
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.